RS66117B1 - Poboljšana veziva serumskog albumina - Google Patents
Poboljšana veziva serumskog albuminaInfo
- Publication number
- RS66117B1 RS66117B1 RS20241215A RSP20241215A RS66117B1 RS 66117 B1 RS66117 B1 RS 66117B1 RS 20241215 A RS20241215 A RS 20241215A RS P20241215 A RSP20241215 A RS P20241215A RS 66117 B1 RS66117 B1 RS 66117B1
- Authority
- RS
- Serbia
- Prior art keywords
- amino acid
- seq
- serum albumin
- compound
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446988P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051083 WO2018134235A1 (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
| EP18707848.0A EP3571225B1 (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66117B1 true RS66117B1 (sr) | 2024-11-29 |
Family
ID=61521465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20241215A RS66117B1 (sr) | 2017-01-17 | 2018-01-17 | Poboljšana veziva serumskog albumina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11414481B2 (enExample) |
| EP (3) | EP4442707A3 (enExample) |
| JP (3) | JP7219220B2 (enExample) |
| KR (2) | KR102662499B1 (enExample) |
| CN (2) | CN110191896B (enExample) |
| AU (2) | AU2018209151B2 (enExample) |
| BR (1) | BR112019014599A2 (enExample) |
| CA (1) | CA3050575A1 (enExample) |
| DK (1) | DK3571225T3 (enExample) |
| ES (1) | ES2991459T3 (enExample) |
| FI (1) | FI3571225T3 (enExample) |
| HR (1) | HRP20241469T1 (enExample) |
| HU (1) | HUE068790T2 (enExample) |
| IL (2) | IL312292A (enExample) |
| LT (1) | LT3571225T (enExample) |
| MX (2) | MX2019008496A (enExample) |
| PT (1) | PT3571225T (enExample) |
| RS (1) | RS66117B1 (enExample) |
| SG (2) | SG11201906264YA (enExample) |
| SI (1) | SI3571225T1 (enExample) |
| WO (1) | WO2018134235A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PH12022550313A1 (en) * | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| IL310340A (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| MX2019008536A (es) * | 2017-01-17 | 2019-09-10 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| KR102662499B1 (ko) * | 2017-01-17 | 2024-05-02 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| MX2022006880A (es) | 2019-12-06 | 2022-07-11 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23. |
| KR20220111313A (ko) | 2019-12-06 | 2022-08-09 | 아블린쓰 엔.브이. | TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| TWI861302B (zh) | 2019-12-09 | 2024-11-11 | 比利時商艾伯霖克斯公司 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| EP4126971A1 (en) | 2020-03-30 | 2023-02-08 | Ablynx N.V. | Method for the production and purification of multivalent immunoglobulin single variable domains |
| MX2023003522A (es) | 2020-09-25 | 2023-04-19 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l. |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| EP4262985A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| PH12023500009A1 (en) | 2020-12-18 | 2024-03-11 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| TW202342508A (zh) | 2021-12-17 | 2023-11-01 | 比利時商艾伯霖克斯公司 | 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽 |
| TW202415678A (zh) | 2022-06-14 | 2024-04-16 | 比利時商艾伯霖克斯公司 | 靶向ｔ細胞受體的免疫球蛋白單可變結構域 |
| JP2025526384A (ja) | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| EP4665755A1 (en) | 2023-02-17 | 2025-12-24 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| KR102822958B1 (ko) * | 2023-05-23 | 2025-06-20 | 대한민국(해양경찰청 해양경찰연구센터장) | 고래 불법포획 감식용 신속진단키트 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| TW202515917A (zh) | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| AR134267A1 (es) | 2023-11-08 | 2025-12-17 | Sanofi Sa | Degradador lisosómico basado en cd25 y usos del mismo |
| TW202540188A (zh) | 2023-12-01 | 2025-10-16 | 比利時商艾伯霖克斯公司 | 精準活化的多肽 |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| TW202547857A (zh) * | 2024-04-12 | 2025-12-16 | 美商派拉岡醫療公司 | 抗ｈａｓ抗體及其組合物 |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
| WO2026006708A2 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026052756A1 (en) | 2024-09-05 | 2026-03-12 | Ablynx Nv | Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| EP1517921B1 (en) | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| WO2006059108A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
| RU2464276C2 (ru) | 2005-05-18 | 2012-10-20 | Аблинкс Н.В. | Улучшенные нанотела против фактора некроза опухоли-альфа |
| DK2444424T3 (en) | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| CN101454344A (zh) | 2005-12-01 | 2009-06-10 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的非竞争性域抗体形式 |
| CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| AU2008252853B2 (en) | 2007-05-24 | 2011-12-01 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| AU2009248049B2 (en) | 2008-05-16 | 2015-07-23 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| LT2334705T (lt) * | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | Biologiniai produktai |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| CN102574914A (zh) | 2009-07-16 | 2012-07-11 | 葛兰素集团有限公司 | 改进的抗血清清蛋白结合性单可变区 |
| KR20120092611A (ko) | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
| JP2013538566A (ja) | 2010-08-13 | 2013-10-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 改良された抗血清アルブミン結合変異体 |
| SG188204A1 (en) | 2010-08-20 | 2013-04-30 | Glaxo Group Ltd | Improved anti-serum albumin binding variants |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP3466972B1 (en) | 2011-06-23 | 2026-03-04 | Ablynx NV | Serum albumin binding proteins |
| PH12022550313A1 (en) * | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| RS55775B2 (sr) * | 2011-06-23 | 2022-10-31 | Ablynx Nv | Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| PH12014500380A1 (en) | 2011-08-17 | 2022-05-02 | Glaxo Group Ltd | Modified proteins and peptides |
| US20130129727A1 (en) * | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| AU2016209247B2 (en) | 2015-01-21 | 2021-02-25 | Inhibrx Biosciences, Inc. | Non-immunogenic single domain antibodies |
| ES2754427T3 (es) | 2015-05-13 | 2020-04-17 | Ablynx Nv | Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta |
| LT3374392T (lt) * | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
| AU2016360987A1 (en) | 2015-11-27 | 2018-06-07 | Ablynx Nv | Polypeptides inhibiting CD40L |
| IL310340A (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| MX2019008536A (es) * | 2017-01-17 | 2019-09-10 | Ablynx Nv | Aglutinantes de albumina serica mejorados. |
| KR102662499B1 (ko) | 2017-01-17 | 2024-05-02 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| AR133903A1 (es) * | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
-
2018
- 2018-01-17 KR KR1020197024113A patent/KR102662499B1/ko active Active
- 2018-01-17 DK DK18707848.0T patent/DK3571225T3/da active
- 2018-01-17 SG SG11201906264YA patent/SG11201906264YA/en unknown
- 2018-01-17 JP JP2019538382A patent/JP7219220B2/ja active Active
- 2018-01-17 MX MX2019008496A patent/MX2019008496A/es unknown
- 2018-01-17 AU AU2018209151A patent/AU2018209151B2/en active Active
- 2018-01-17 CN CN201880007313.6A patent/CN110191896B/zh active Active
- 2018-01-17 LT LTEPPCT/EP2018/051083T patent/LT3571225T/lt unknown
- 2018-01-17 RS RS20241215A patent/RS66117B1/sr unknown
- 2018-01-17 WO PCT/EP2018/051083 patent/WO2018134235A1/en not_active Ceased
- 2018-01-17 ES ES18707848T patent/ES2991459T3/es active Active
- 2018-01-17 PT PT187078480T patent/PT3571225T/pt unknown
- 2018-01-17 CA CA3050575A patent/CA3050575A1/en active Pending
- 2018-01-17 IL IL312292A patent/IL312292A/en unknown
- 2018-01-17 EP EP24191388.8A patent/EP4442707A3/en active Pending
- 2018-01-17 KR KR1020247002265A patent/KR20240013861A/ko not_active Ceased
- 2018-01-17 CN CN202311123454.3A patent/CN117285623A/zh active Pending
- 2018-01-17 IL IL267894A patent/IL267894B2/en unknown
- 2018-01-17 SI SI201831169T patent/SI3571225T1/sl unknown
- 2018-01-17 SG SG10202108972RA patent/SG10202108972RA/en unknown
- 2018-01-17 FI FIEP18707848.0T patent/FI3571225T3/fi active
- 2018-01-17 US US16/477,918 patent/US11414481B2/en active Active
- 2018-01-17 EP EP18707848.0A patent/EP3571225B1/en active Active
- 2018-01-17 HU HUE18707848A patent/HUE068790T2/hu unknown
- 2018-01-17 HR HRP20241469TT patent/HRP20241469T1/hr unknown
- 2018-01-17 EP EP24191393.8A patent/EP4442709A3/en active Pending
- 2018-01-17 BR BR112019014599-0A patent/BR112019014599A2/pt unknown
-
2019
- 2019-07-16 MX MX2023005374A patent/MX2023005374A/es unknown
-
2022
- 2022-06-29 US US17/852,604 patent/US20230060574A1/en active Pending
- 2022-12-08 JP JP2022196232A patent/JP7628996B2/ja active Active
-
2024
- 2024-11-22 JP JP2024204085A patent/JP2025026992A/ja active Pending
-
2025
- 2025-05-13 AU AU2025203430A patent/AU2025203430A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230060574A1 (en) | Serum albumin binders | |
| US20240294617A1 (en) | Serum albumin binders | |
| US20230050615A1 (en) | Improved serum albumin binding immunoglobulin single variable domains | |
| HK40118030A (en) | Improved serum albumin binders | |
| HK40117444A (en) | Improved serum albumin binders | |
| HK40119626A (en) | Improved serum albumin binders | |
| HK40116819A (en) | Improved serum albumin binders | |
| HK40018516A (en) | Improved serum albumin binders | |
| HK40018516B (en) | Improved serum albumin binders | |
| HK40017968B (en) | Improved serum albumin binders | |
| HK40017968A (en) | Improved serum albumin binders |